8-K: Microbot Medical Secures $15.6 Million in Registered Direct Offerings and Private Placements, Awaits FDA Clearance for LIBERTY System

Microbot Medical announces the closing of registered direct offerings and concurrent private placements, raising $15.6 million, and anticipates FDA clearance for its LIBERTY Endovascular Robotic System in Q2 2025.

Summary

• Microbot Medical Inc., a clinical-stage medical device company, focuses on developing robotic endoluminal surgery devices.
• The company is developing the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for endovascular interventional procedures.
• On January 6 and 7, 2025, Microbot entered into securities purchase agreements for registered direct offerings and concurrent private placements.
• These offerings raised approximately $15.6 million in aggregate gross proceeds before deducting fees and expenses.
• The company issued shares of common stock and series G and H preferred investment options to investors.
• Warrants to purchase common stock were also issued to the placement agent.
• Through January 7, 2025, Microbot sold 4,276,486 shares under an ATM agreement for gross proceeds of $4,819,278.
• As of January 7, 2025, Microbot had 24,242,120 shares of common stock issued and outstanding.
• On December 10, 2024, Microbot submitted a 510(k) premarket notification to the FDA for the LIBERTY system.
• FDA marketing clearance is anticipated during the second quarter of 2025, with U.S. commercialization expected to follow.
• The company is monitoring the impact of the Israel-Hamas war on its operations, particularly its research and development in Israel.
• As of September 30, 2024, Microbot had a net working capital of approximately $3.6 million, which does not include the $20.6 million raised subsequently.
• Since inception through January 31, 2025, Microbot has raised approximately $93.4 million.
• Since inception through September 30, 2024, Microbot incurred a total cumulative loss of approximately $87.5 million.
• Management believes the company has sufficient funds for operations for in excess of one year.
• The main competitor is the CorPath GRX vascular robotics system by Corindus Vascular Robotics, a Siemens Healthineers company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company has successfully raised capital and is anticipating FDA clearance, but it also faces ongoing losses and competition.

Positives

• Successful capital raises of $15.6 million in January 2025 strengthen the company's financial position.
• Anticipated FDA clearance for the LIBERTY system in Q2 2025 could lead to commercialization and revenue generation.
• Management believes the company has sufficient funds for operations for in excess of one year.
• The company has raised approximately $93.4 million since inception.

Negatives

• Microbot Medical has incurred losses since inception and negative cash flows from operating activities.
• As of September 30, 2024, the company had a net working capital of approximately $3.6 million.
• The company has a cumulative loss of approximately $87.5 million since inception through September 30, 2024.
• The company is dependent on raising additional capital to fund its commercial activities and working capital.

Risks

• The company's operations, particularly research and development in Israel, could be adversely affected by the ongoing Israel-Hamas war.
• The company faces competition from established players like Corindus Vascular Robotics and other emerging technologies.
• The company's existing and planned products could be rendered obsolete by technological advances from competitors.
• The company may not be able to secure financing in the amounts it needs, at the times it needs it or on terms acceptable to it.
• Future capital raises could result in additional dilution to Microbot's shareholders.

Future Outlook

Microbot Medical anticipates FDA marketing clearance for its LIBERTY Endovascular Robotic System during the second quarter of 2025, with U.S. commercialization activities expected to commence after the clearance. The company intends to continue to raise capital through future public and private issuances of debt and/or equity securities to fund its commercial activities and working capital.

Industry Context

The medical robotics industry is competitive, with players like Corindus Vascular Robotics (a Siemens Healthineers company) and Robocath already having approved systems. Microbot's LIBERTY system aims to differentiate itself through its fully disposable design and potential for reduced capital equipment costs.

Comparison to Industry Standards

• Corindus Vascular Robotics' CorPath GRX system is a key competitor, holding FDA approval and CE marking for percutaneous coronary and vascular procedures, and CE marking for neurovascular interventions.
• Robocath has CE Marking, NMPA, South Africa for PCI only.
• LN Robotics is approved in Korea for coronary interventions.
• Microbot's LIBERTY system aims to address drawbacks of existing systems, such as limited maneuverability and high capital expenditures.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises.
• Employees' jobs could be affected by the company's financial performance and the success of the LIBERTY system.
• Customers (healthcare providers) could benefit from the LIBERTY system's potential to improve surgical outcomes.
• Suppliers and vendors could see increased business if the LIBERTY system is successful.
• Creditors face the risk of non-payment if the company's financial performance does not improve.

Next Steps

• Await FDA marketing clearance for the LIBERTY Endovascular Robotic System.
• Commence U.S. commercialization activities after FDA clearance.
• Continue research and development efforts.
• Potentially raise additional capital through public and private issuances.

Key Dates

Keywords

Microbot Medical, LIBERTY Endovascular Robotic Surgical System, Registered Direct Offering, Private Placement, FDA Clearance, Endovascular Robotics, Medical Device, Capital Raise